OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 21:49 UTC. Every row links to its source record.

FEV FEV transcription factor, ETS family member

ENSG00000163497 · protein coding · Open Targets profile

Functions as a transcriptional regulator. According to PubMed:12761502, it functions as a transcriptional repressor. Functions in the differentiation and the maintenance of the central serotonergic neurons. May play a role in cell growth. .

In 15 of 15 cancers, the evidence for FEV comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751malignant soft tissue neoplasmmalignant soft tissue neoplasmmalignant soft tissue neoplasm: somatic 0.61olfactory neuroblastomaolfactory neuroblastomaolfactory neuroblastoma: somatic 0.61extraskeletal Ewing sarcoma/peripheral …extraskeletal Ewing sarcoma/peripheral primitive neuroectodermal tumorextraskeletal Ewing sarcoma/peripheral primitive neuroectodermal tumor: somatic 0.61Ewing sarcoma/peripheral primitive neur…Ewing sarcoma/peripheral primitive neuroectodermal tumor of boneEwing sarcoma/peripheral primitive neuroectodermal tumor of bone: somatic 0.61colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.46prostate adenocarcinomaprostate adenocarcinomaprostate adenocarcinoma: somatic 0.46gastric adenocarcinomagastric adenocarcinomagastric adenocarcinoma: somatic 0.46hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.46colon adenocarcinomacolon adenocarcinomacolon adenocarcinoma: somatic 0.46non-small cell lung carcinomanon-small cell lung carcinomanon-small cell lung carcinoma: somatic 0.46thyroid gland carcinomathyroid gland carcinomathyroid gland carcinoma: somatic 0.46pancreatic ductal adenocarcinomapancreatic ductal adenocarcinomapancreatic ductal adenocarcinoma: somatic 0.46parathyroid gland carcinomaparathyroid gland carcinomaparathyroid gland carcinoma: somatic 0.46breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.46endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
Database Ubiquitination

gnomAD loss of function constraint: o/e 0.6827499866485596 (upper bound 1.0673999786376953). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of FEV's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of FEV's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.